Silverback Therapeutics is halting the company’s clinical oncology programs and letting go of about 27% of its workforce as part of a restructuring initiative that would leave Silverback with more cash reserves.
Following Lab Test, Eagle Pharma Looks to Test MH Drug Ryanodex Against COVID-19
Antiviral Activity, Clinical Trials, Coronavirus Disease (COVID-19) Pandemic, Cytotoxicity, Hackensack University Medical Center, Laboratory Tests, Malignant Hyperthermia, R&D, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)In a controlled laboratory test, Eagle Pharmaceuticals’ malignant hyperthermia treatment Ryanodex (dantrolene sodium) inhibited the growth of SARS-CoV-2, the virus causing the COVID-19 pandemic. The company hopes to launch a clinical trial testing the efficacy of the drug in patients.